Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Astex Pharmaceuticals, Inc. (ASTX), GlaxoSmithKline plc (ADR) (GSK), Cytokinetics, Inc. (CYTK): Last Week in Biotech

Page 1 of 2

With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let’s have a look at some of the rulings, studies, and companies that made waves in the sector last week.

Astex Pharmaceuticals, Inc. (NASDAQ:ASTX)

As always, we’ll lead off with the feel-good stories for the week — and nothing made shareholders of Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) feel better than the announcement on Thursday that Japan’s Otsuka Holdings will buy Astex for $804 million, or $8.50 per share. The price of the deal represents a 30% premium from where Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) began the week. With this purchase, Otsuka gains access to FDA-approved myelodysplastic syndrome drug Dacogen, as well as a promising pipeline of cancer drugs, including SGI-110 which delivered positive top-line results in a mid-stage acute myeloid leukemia trial last week. In my opinion, I’d say Otsuka is getting an absolute steal of a deal on Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) given its strong cash position, multiple big pharmaceutical partnerships, and the recent favorable results in its pipeline. The market may feel this way as well with Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) current finishing the week slightly ahead of its offer price.

The remaining noteworthy stories this week were all related in one way or another to a positive or negative reaction to clinical-stage data.

In the plus column, Rockwell Medical Inc (NASDAQ:RMTI) even trumped Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), rising a clean 50% this week following positive late-stage study results of soluble ferric phosphate, or SFP, an iron replacement therapy for chronic kidney disease patients that are on dialysis. The study demonstrated that SFP met both its primary endpoint (statistically significant change in hemoglobin levels from the start to end of the study) and secondary endpoints (maintenance of hemoglobin, reticulocyte hemoglobin, and increase in serum iron in pre-to-post treatment without an increase in ferritin). With a good shot of becoming the go-to iron replacement therapy thanks to its superior safety results, Rockwell Medical Inc (NASDAQ:RMTI) shareholders certainly have something to cheer about. Expect Rockwell Medical Inc (NASDAQ:RMTI) to file for a new drug application within the next couple of months.

Also delivering shareholder-pleasing clinical data this week was the chronic obstructive pulmonary disease (COPD) “little giant” Theravance Inc (NASDAQ:THRX). On Wednesday, Theravance Inc (NASDAQ:THRX) announced that its phase 2b trial involving in-house and wholly owned drug TD-4208, a long-acting muscarinic antagonist, met both its primary and secondary endpoints in the study which included a change in FEV1 (forced expiratory volume in one second) by day seven, and demonstrated the potential of being a once-daily treatment .

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!